{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:20:24Z","timestamp":1760059224998,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Champions Oncology","award":["41081"],"award-info":[{"award-number":["41081"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Humanized mice generated by hematopoietic stem cell (HSC) transplantation are limited by the immune system developed being allogeneic to the tumor. We have innovated a platform to reconstitute an autologous human immune system (HIS) in immunodeficient NOG-EXL mice from mobilized peripheral blood (MPB)-CD34 cells, along with PDX generated from the same patient\u2019s tumor tissue. Patients consented under an IRB-approved protocol for tumor biopsy and HSC apheresis at Emory University. HSC collection included mobilization with G-CSF and plerixafor, immunomagnetic bead isolation with CliniMACS, and cryopreservation of CD34+ cells. PDX were established from biopsies or surgical specimens by passaging into immunodeficient mice. Irradiated NOG-EXL mice were engrafted with HSCs by intravenous transplantation of CD34+ HSC. Engraftment of human T cells, B cells, and myeloid cells in peripheral blood was assessed by serial flow cytometry of blood samples, with final assessment of immune components in spleen and bone marrow at 30 weeks. Twenty-eight PDX models were generated from 43 patients with HNSCC; 1 patient underwent apheresis. HSC engraftment in blood was observed in 100% of NOG-EXL mice at 8 weeks post-transplant, with 5\u201320% hCD45+ cells present in the periphery. B-cell development was predominant at early time points and declined over time. Human T-cell and subset development of CD4+ and CD8+ T cells were observed in blood from 15 weeks post-transplant. Strong development of the myeloid lineage (CD33+) was observed starting at 8 weeks and persisted throughout the study. These data demonstrate that mobilization and apheresis of HNSCC patients is technically and clinically feasible and may allow the establishment of autologous HIS-PDX mice.<\/jats:p>","DOI":"10.3390\/ijms26115269","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:14:27Z","timestamp":1748585667000},"page":"5269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient"],"prefix":"10.3390","volume":"26","author":[{"given":"Bhavna","family":"Verma","sequence":"first","affiliation":[{"name":"Champions Oncology, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-1926","authenticated-orcid":false,"given":"Georgia Zhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir","family":"Patel","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"},{"name":"Department of Otolaryngology, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Anderson","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Champions Oncology, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4917-5165","authenticated-orcid":false,"given":"Amy","family":"Wesa","sequence":"additional","affiliation":[{"name":"Champions Oncology, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-7289","authenticated-orcid":false,"given":"Yong","family":"Teng","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"},{"name":"Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-1477","authenticated-orcid":false,"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA 20850, USA"},{"name":"Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1200\/JCO.2016.34.15_suppl.6011","article-title":"Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).Oral abstract at ASCO meeting 2016","volume":"34","author":"Bauml","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41591-023-02275-x","article-title":"Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: A phase 2 trial","volume":"29","author":"Saba","year":"2023","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","article-title":"Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma","volume":"13","author":"Elmusrati","year":"2021","journal-title":"Int. J. Oral. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","article-title":"Patient-derived tumor xenografts: Transforming clinical samples into mouse models","volume":"73","author":"Siolas","year":"2013","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kanikarla Marie, P., Sorokin, A.V., Bitner, L.A., Aden, R., Lam, M., Manyam, G., Woods, M.N., Anderson, A., Capasso, A., and Fowlkes, N. (2022). Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.994333"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-16-0558","article-title":"HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2\/HER3 dimerization\u2014Evidence from cell line and patient derived xenograft models","volume":"23","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12105-014-0566-0","article-title":"Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle","volume":"9","author":"Saba","year":"2015","journal-title":"Head Neck Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Janakiraman, H., Becker, S.A., Bradshaw, A., Rubinstein, M.P., and Camp, E.R. (2022). Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0273076"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1002\/cpph.77","article-title":"Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents","volume":"89","author":"Verma","year":"2020","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.4049\/jimmunol.167.7.3692","article-title":"Both CD34+38+ and CD34+38\u2212 cells home specifically to the bone marrow of NOD\/LtSZ scid\/scid mice but show different kinetics in expansion","volume":"167","author":"Kerre","year":"2001","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4049\/jimmunol.169.1.204","article-title":"Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic\/Shi-scid, IL-2 receptor gamma null mice","volume":"169","author":"Yahata","year":"2002","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ng, E.S., Sarila, G., Li, J.Y., Edirisinghe, H.S., Saxena, R., Sun, S., Bruveris, F.F., Labonne, T., Sleebs, N., and Maytum, A. (2024). Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells. Nat. Biotechnol.","DOI":"10.1038\/s41587-024-02360-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood.V87.8.3237.bloodjournal8783237","article-title":"Developmental potential of different sources of human hematopoietic progenitor cells in BNX mice","volume":"87","author":"Turner","year":"1996","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13287-024-03799-w","article-title":"Improvement of multilineage hematopoiesis in hematopoietic stem cell-transferred c-kit mutant NOG-EXL humanized mice","volume":"15","author":"Ito","year":"2024","journal-title":"Stem. Cell Res. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:50Z","timestamp":1760031830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115269"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115269","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}